Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole Orodispersible Film Bioequivalence Study
NCT04819438Phase 1Completed
- Sponsor
- CROSS Research
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of riluzole in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by CROSS Research. Primary endpoints: Maximum Plasma Concentration at 36 hours and Area Under the Curve from time 0 to the last measurable concentration at 36 hours. Started Jan 2021; status: completed.
02
Drugs
riluzole
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04819438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04819438.